ATYR PHARMA INC (LIFE) Stock Price, Quote, News and Overview
NASDAQ:LIFE - Nasdaq - US0021202025 - Common Stock - Currency: USD
LIFE Quote, Performance and Key Statistics
1.9
+0.05 (+2.7%)
The current stock price of LIFE is 1.9 USD. In the past month the price increased by 14.46%. In the past year, price decreased by -13.64%.
LIFE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LIFE
Company Profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 65 full-time employees. The company went IPO on 2015-05-07. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. The company is also advancing its preclinical pipeline of tRNA synthetases and NRP2. The company has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.
Company Info
ATYR PHARMA INC
10240 Sorrento Valley Road, Suite 300
San Diego CALIFORNIA 92121 US
CEO: Sanjay S. Shukla
Employees: 65
Company Website: https://www.atyrpharma.com/
Phone: 18587318389
ATYR PHARMA INC / LIFE FAQ
What is the stock price of ATYR PHARMA INC today?
The current stock price of LIFE is 1.9 USD. The price increased by 2.7% in the last trading session.
What is the ticker symbol for ATYR PHARMA INC stock?
The exchange symbol of ATYR PHARMA INC is LIFE and it is listed on the Nasdaq exchange.
On which exchange is LIFE stock listed?
LIFE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATYR PHARMA INC stock?
11 analysts have analysed LIFE and the average price target is 25.09 USD. This implies a price increase of 1220.63% is expected in the next year compared to the current price of 1.9. Check the ATYR PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATYR PHARMA INC worth?
ATYR PHARMA INC (LIFE) has a market capitalization of 129.87M USD. This makes LIFE a Micro Cap stock.
How many employees does ATYR PHARMA INC have?
ATYR PHARMA INC (LIFE) currently has 65 employees.
What are the support and resistance levels for ATYR PHARMA INC (LIFE) stock?
ATYR PHARMA INC (LIFE) has a support level at 1.68 and a resistance level at 1.94. Check the full technical report for a detailed analysis of LIFE support and resistance levels.
Is ATYR PHARMA INC (LIFE) expected to grow?
The Revenue of ATYR PHARMA INC (LIFE) is expected to decline by -19.38% in the next year. Check the estimates tab for more information on the LIFE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATYR PHARMA INC (LIFE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LIFE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LIFE, evaluating the profitability, health, valuation and growth aspects
- ATYR PHARMA INC (LIFE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATYR PHARMA INC (LIFE) Sales and EPS estimates to see what analysts future expectations are.
- ATYR PHARMA INC (LIFE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATYR PHARMA INC (LIFE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATYR PHARMA INC (LIFE) Stock Chart to make your own analysis
- ATYR PHARMA INC (LIFE) Latest news and press-releases to stay up to date.
Does ATYR PHARMA INC (LIFE) stock pay dividends?
LIFE does not pay a dividend.
When does ATYR PHARMA INC (LIFE) report earnings?
ATYR PHARMA INC (LIFE) will report earnings on 2024-08-07, after the market close.
What is the Price/Earnings (PE) ratio of ATYR PHARMA INC (LIFE)?
ATYR PHARMA INC (LIFE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
LIFE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LIFE. When comparing the yearly performance of all stocks, LIFE turns out to be only a medium performer in the overall market: it outperformed 56.36% of all stocks.
LIFE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIFE. LIFE has a bad profitability rating. Also its financial health evaluation is rather negative.
LIFE Financial Highlights
Over the last trailing twelve months LIFE reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 37.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| Debt/Equity | 0.02 |
LIFE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to LIFE. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 2.52% and a revenue growth -19.38% for LIFE